PL355262A1 - Sposób podawania inhibitora fosfodiesterazy 4 - Google Patents

Sposób podawania inhibitora fosfodiesterazy 4

Info

Publication number
PL355262A1
PL355262A1 PL00355262A PL35526200A PL355262A1 PL 355262 A1 PL355262 A1 PL 355262A1 PL 00355262 A PL00355262 A PL 00355262A PL 35526200 A PL35526200 A PL 35526200A PL 355262 A1 PL355262 A1 PL 355262A1
Authority
PL
Poland
Prior art keywords
phosphodiesterase
administering
inhibitor
Prior art date
Application number
PL00355262A
Other languages
English (en)
Inventor
Robert D. Murdoch
Theodore J. Torphy
Barry D. Zussman
Original Assignee
Smithkline Beecham Corporation
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, Smithkline Beecham P.L.C. filed Critical Smithkline Beecham Corporation
Publication of PL355262A1 publication Critical patent/PL355262A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
PL00355262A 1999-10-29 2000-10-26 Sposób podawania inhibitora fosfodiesterazy 4 PL355262A1 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16247799P 1999-10-29 1999-10-29
US16264199P 1999-11-01 1999-11-01
US17981700P 2000-02-02 2000-02-02
PCT/US2000/029453 WO2001032165A1 (en) 1999-10-29 2000-10-26 Method for administering a phosphodiesterase 4 inhibitor

Publications (1)

Publication Number Publication Date
PL355262A1 true PL355262A1 (pl) 2004-04-05

Family

ID=27388757

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00355262A PL355262A1 (pl) 1999-10-29 2000-10-26 Sposób podawania inhibitora fosfodiesterazy 4

Country Status (29)

Country Link
US (1) US20030212112A1 (pl)
EP (1) EP1225884A4 (pl)
JP (1) JP2003513038A (pl)
KR (1) KR20020050249A (pl)
CN (1) CN1387433A (pl)
AP (1) AP2002002446A0 (pl)
AR (1) AR026254A1 (pl)
AU (1) AU772909B2 (pl)
BG (1) BG106623A (pl)
BR (1) BR0015039A (pl)
CA (1) CA2389293A1 (pl)
CO (1) CO5271676A1 (pl)
CZ (1) CZ20021443A3 (pl)
DZ (1) DZ3249A1 (pl)
EA (1) EA200200502A1 (pl)
HK (1) HK1049105A1 (pl)
HU (1) HUP0203682A3 (pl)
IL (1) IL148813A0 (pl)
MA (1) MA25562A1 (pl)
MX (1) MXPA02004220A (pl)
NO (1) NO20021937L (pl)
NZ (1) NZ518002A (pl)
OA (1) OA12078A (pl)
PE (1) PE20011004A1 (pl)
PL (1) PL355262A1 (pl)
SK (1) SK7292002A3 (pl)
TR (1) TR200201150T2 (pl)
UY (1) UY26422A1 (pl)
WO (1) WO2001032165A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20060084684A1 (en) * 2002-05-28 2006-04-20 Altana Pharma Ag Topically applicable pharmaceutical preparation
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
WO2004096274A1 (ja) * 2003-03-31 2004-11-11 Kyowa Hakko Kogyo Co., Ltd. 気道内投与剤
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
ES2421916T3 (es) 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
KR101763440B1 (ko) * 2009-12-03 2017-08-14 옵코 헬스, 인크. 과황산화 이당 제제
AU2012362562B2 (en) * 2011-12-27 2017-11-02 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
CN103536582A (zh) * 2013-10-12 2014-01-29 云南龙海天然植物药业有限公司 罗氟司特干粉吸入剂
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
MY121142A (en) * 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
AR035987A1 (es) * 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio

Also Published As

Publication number Publication date
BR0015039A (pt) 2002-06-25
EA200200502A1 (ru) 2002-10-31
CZ20021443A3 (cs) 2003-01-15
OA12078A (en) 2003-05-28
NZ518002A (en) 2004-01-30
SK7292002A3 (en) 2002-12-03
EP1225884A1 (en) 2002-07-31
IL148813A0 (en) 2002-09-12
AU1344501A (en) 2001-05-14
EP1225884A4 (en) 2005-06-15
HUP0203682A2 (hu) 2003-04-28
NO20021937L (no) 2002-05-30
AU772909B2 (en) 2004-05-13
AP2002002446A0 (en) 2002-03-31
JP2003513038A (ja) 2003-04-08
MA25562A1 (fr) 2002-10-01
TR200201150T2 (tr) 2002-09-23
HUP0203682A3 (en) 2003-10-28
UY26422A1 (es) 2001-07-31
CO5271676A1 (es) 2003-04-30
PE20011004A1 (es) 2001-09-28
DZ3249A1 (fr) 2001-05-10
NO20021937D0 (no) 2002-04-24
WO2001032165A1 (en) 2001-05-10
CN1387433A (zh) 2002-12-25
US20030212112A1 (en) 2003-11-13
AR026254A1 (es) 2003-02-05
BG106623A (bg) 2003-02-28
CA2389293A1 (en) 2001-05-10
KR20020050249A (ko) 2002-06-26
HK1049105A1 (zh) 2003-05-02
MXPA02004220A (es) 2002-10-17

Similar Documents

Publication Publication Date Title
IL141445A0 (en) Benzazine derivatives as phosphodiesterase 4 inhibitors
IL146002A0 (en) Renin inhibitors
GB9900416D0 (en) Inhibitors
ZA98376B (en) Sulfamide-metalloprotease inhibitors
HUP0103349A3 (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors
IL130802A0 (en) Sulfamide-metalloprotease inhibitors
PL362903A1 (pl) Inhibitory reniny
HUP0203682A3 (en) Method for administering a phosphodiesterase 4 inhibitor
AU2274299A (en) Benzazine derivatives phosphodiesterase 4 inhibitors
HUP0000536A2 (en) Method for levelling a track
PL345187A1 (en) Phthalazine derivatives phosphodiesterase 4 inhibitors
IL141446A0 (en) Benzazine derivatives as phosphodiesterase 4 inhibitors
MY133515A (en) Shim removing tool
EP1237112A4 (en) METHOD OF MAKING SECURE TRANSACTIONS ON ELECTRONIC BANKING BOOK (TIRELIRE)
GB9925659D0 (en) A method of verification
EP1153022A4 (en) PROTEASE INHIBITORS
PL346842A1 (en) New pharmaceutical uses for nos inhibitors
GB2389113B (en) B-secretase inhibitor
HUP0200455A3 (en) Method for producing 4-amino-5-chloro-1-phenyl pyridazinone-(6)
GB9823341D0 (en) Process for phosphodiesterase iv inhibitors
GB9906058D0 (en) A method for the quantitative detrmination of D N A
GB9914436D0 (en) A method
GB2314014B (en) Closure-arrangements for loose-covers
GB9901166D0 (en) A set of parts
GB9922470D0 (en) A set of parts

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)